Table 2 Studies included in comparisons. (a) 1 LVEF 44 trails, (b) LVEDD 8 trails, (c) LVESD 6 trails, (d) LVEDV 17 trails, (e) LVESV 15 trails, (f) LVMI 15 trails, (g) E/e′ 11 trails, (h) e′ 5 trails, (i) E/A 14 trails included
Treatment | No. of trials | Total no. of patients |
|---|---|---|
a) LVEF 44 trails | ||
 Control | 38 | 1635 |
 DPP-4 inhibitor | 9 | 421 |
 GLP-1 agonist | 24 | 991 |
 MET | 5 | 242 |
 SGLT-2 inhibitor | 3 | 53 |
 SU | 4 | 242 |
 TZDs | 7 | 357 |
b) LVEDD 8 trails | ||
 Control | 7 | 542 |
 DPP-4 inhibitor | 2 | 126 |
 GLP-1 agonist | 4 | 399 |
 MET | 1 | 30 |
 SGLT-2 inhibitor | 1 | 21 |
 TZDs | 1 | 42 |
c) LVESD 6 trails | ||
 Control | 6 | 476 |
 DPP-4 inhibitor | 1 | 55 |
 GLP-1 agonist | 3 | 369 |
 SGLT-2 inhibitor | 1 | 21 |
 TZDs | 1 | 42 |
d) LVEDV 17 trails | ||
 Control | 15 | 915 |
 DPP-4 inhibitor | 2 | 163 |
 GLP-1 agonist | 11 | 621 |
 MET | 2 | 157 |
 SGLT-2 inhibitor | 1 | 17 |
 SU | 1 | 60 |
 TZDs | 2 | 97 |
e) LVESV 15 trails | ||
 Control | 14 | 858 |
 DPP-4 inhibitor | 1 | 92 |
 GLP-1 agonist | 11 | 621 |
 MET | 3 | 173 |
 TZDs | 2 | 52 |
f) LVMI 15 trails | ||
 Control | 11 | 416 |
 DPP-4 inhibitor | 5 | 162 |
 GLP-1 agonist | 5 | 92 |
 MET | 2 | 149 |
 SU | 3 | 249 |
 TZDs | 4 | 243 |
g) E/e′ 11 trails | ||
 Control | 9 | 430 |
 DPP-4 inhibitor | 3 | 72 |
 GLP-1 agonist | 6 | 226 |
 MET | 1 | 118 |
 SGLT-2 inhibitor | 1 | 21 |
 SU | 1 | 22 |
 TZDs | 1 | 42 |
h) e′ 5 trails | ||
 Control | 5 | 341 |
 DPP-4 inhibitor | 2 | 40 |
 GLP-1 agonist | 1 | 122 |
 MET | 1 | 118 |
 TZDs | 1 | 42 |
i) E/A 14 trails | ||
 Control | 10 | 378 |
 DPP-4 inhibitor | 4 | 82 |
 GLP-1 agonist | 8 | 200 |
 MET | 4 | 217 |
 SGLT-2 inhibitor | 1 | 21 |
 TZDs | 2 | 81 |